Evofem Inc Drug Patent Portfolio
Evofem Inc owns 2 orange book drugs protected by 15 US patents Given below is the list of Evofem Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11684607 | Secnidazole for use in the treatment of bacterial vaginosis | 16 Sep, 2035 | Active |
| US10335390 | Secnidazole for use in the treatment of bacterial vaginosis | 04 Sep, 2035 | Active |
| US10682338 | Secnidazole for use in the treatment of bacterial vaginosis | 04 Sep, 2035 | Active |
| US10849884 | Secnidazole for use in the treatment of bacterial vaginosis | 04 Sep, 2035 | Active |
| US10857133 | Secnidazole for use in the treatment of bacterial vaginosis | 04 Sep, 2035 | Active |
| US11000507 | Secnidazole for use in the treatment of bacterial vaginosis | 04 Sep, 2035 | Active |
| US11000508 | Secnidazole for use in the treatment of trichomoniasis | 04 Sep, 2035 | Active |
| US11020377 | Secnidazole for use in the treatment of bacterial vaginosis | 04 Sep, 2035 | Active |
| US11324721 | Secnidazole for use in the treatment of trichomoniasis | 04 Sep, 2035 | Active |
| US11602522 | Secnidazole for use in the treatment of sexually transmitted infection | 04 Sep, 2035 | Active |
| US10568855 | Compositions and methods for enhancing the efficacy of contraceptive microbicides | 15 Mar, 2033 | Active |
| US11337989 | Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound | 15 Mar, 2033 | Active |
| US11439610 | Compositions and methods for enhancing the efficacy of contraceptive microbicides | 15 Mar, 2033 | Active |
| US11992472 | Compositions and methods for enhancing the efficacy of contraceptive microbicides | 15 Mar, 2033 | Active |
| US6706276 | Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa | 06 Mar, 2024 | Expired |
Latest Legal Activities on Evofem Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Evofem Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Jul, 2024 | US11000508 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Jul, 2024 | US11000507 |
|
Interim Patent Term Extension Granted
Critical
| 30 Jan, 2024 | US6706276 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Dec, 2023 | US10857133 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Dec, 2023 | US10849884 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 08 Sep, 2023 | US11337989 |
|
Email Notification
Critical
| 08 Sep, 2023 | US11337989 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 09 Aug, 2023 | US10568855 |
|
Interim Patent Term Extension Granted
Critical
| 04 Aug, 2023 | US6706276 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Jun, 2023 | US10682338 |
|
Email Notification
Critical
| 27 Jun, 2023 | US11684607 |
|
Electronic Review
Critical
| 27 Jun, 2023 | US11684607 |
| Patent eGrant Notification | 27 Jun, 2023 | US11684607 |
| Mail Patent eGrant Notification | 27 Jun, 2023 | US11684607 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 27 Jun, 2023 | US11684607 |
Evofem Inc's Family Patents
Evofem Inc drugs have patent protection in a total of 23 countries. It's US patent count contributes only to 32.3% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Evofem Inc Drug List
Given below is the complete list of Evofem Inc's drugs and the patents protecting them.
1. Phexxi
Phexxi is protected by 5 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10568855 | Compositions and methods for enhancing the efficacy of contraceptive microbicides |
15 Mar, 2033
(8 years from now)
| Active |
| US11337989 | Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound |
15 Mar, 2033
(8 years from now)
| Active |
| US11439610 | Compositions and methods for enhancing the efficacy of contraceptive microbicides |
15 Mar, 2033
(8 years from now)
| Active |
| US11992472 | Compositions and methods for enhancing the efficacy of contraceptive microbicides |
15 Mar, 2033
(8 years from now)
| Active |
| US6706276 | Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa |
06 Mar, 2024
(7 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Phexxi's drug page
2. Solosec
Solosec is protected by 10 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11684607 | Secnidazole for use in the treatment of bacterial vaginosis |
16 Sep, 2035
(10 years from now)
| Active |
| US10335390 | Secnidazole for use in the treatment of bacterial vaginosis |
04 Sep, 2035
(10 years from now)
| Active |
| US10682338 | Secnidazole for use in the treatment of bacterial vaginosis |
04 Sep, 2035
(10 years from now)
| Active |
| US10849884 | Secnidazole for use in the treatment of bacterial vaginosis |
04 Sep, 2035
(10 years from now)
| Active |
| US10857133 | Secnidazole for use in the treatment of bacterial vaginosis |
04 Sep, 2035
(10 years from now)
| Active |
| US11000507 | Secnidazole for use in the treatment of bacterial vaginosis |
04 Sep, 2035
(10 years from now)
| Active |
| US11000508 | Secnidazole for use in the treatment of trichomoniasis |
04 Sep, 2035
(10 years from now)
| Active |
| US11020377 | Secnidazole for use in the treatment of bacterial vaginosis |
04 Sep, 2035
(10 years from now)
| Active |
| US11324721 | Secnidazole for use in the treatment of trichomoniasis |
04 Sep, 2035
(10 years from now)
| Active |
| US11602522 | Secnidazole for use in the treatment of sexually transmitted infection |
04 Sep, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Solosec's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List